All In Biotech

NDA 017808 · Mylan Ireland LTD

Miacalcin

Calcitonin Salmon · Injection · Calcitonin

Last checked: Nov 19, 2026Latest source record: Sep 11, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jul 3, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

81

15 Phase 3, 11 recruiting

FAERS reports

3,123

2,212 serious, 279 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 15, 2024.

Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: • Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 ) 1.1 Treatment of Paget’s Disease of Bone Miacalcin injection is indicated for the treatment of symptomatic Paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. There is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. Miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). 1.2 Treatment of Hypercalcemia Miacalcin injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. 1.3 Treatment of Postmenopausal Osteoporosis Miacalcin injection is indicated for the treatment of...

Mechanism: Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastro-intestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MIACALCIN · CALCITONIN SALMON 100 IU/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • MIACALCIN · CALCITONIN SALMON 200 IU/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Calcitonin Salmon" as an intervention, any sponsor and status, largest first.

All 81 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea253
  • drug ineffective249
  • fall221
  • pain213
  • arthralgia189
  • dizziness184
  • headache178
  • back pain173
  • dyspnoea164
  • asthenia156
  • fatigue156
  • diarrhoea146

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004429
2005335
2006243
2007144
2008152
2009150
2010176
2011176
2012212
201363
201465
2015142
2016112
2017108
201881
201991
202055
202139
202273
202381
202473
202579
202644

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Miacalcin (Calcitonin,Salmon,Synthetic)

2024 spending

$712K

Beneficiaries

13

45 claims

Per beneficiary

$54,768

$1,338.31 per unit

View as table
YearSpending
2020$5,154,663
2021$3,173,521
2022$980,104
2023$836,655
2024$711,979

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Mylan Ireland LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.